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To the Editor: 
Survival differences with hemodialysis (HD) or peritoneal dialysis (PD) in patients 
with end-stage renal disease (ESRD), may vary substantially according to 
demographics or comorbidities1. In that regard, intra-dialytic hypotension can induce 
myocardial stunning that contributes to heart failure in HD patients2, and may be 
detrimental to ESRD patients with concomitant ischemic cardiomyopathy (ICMP). 
However, PD obviates the need for a high-flow arteriovenous fistula and allows 
gradual daily ultrafiltration, both likely favorable for patients with ICMP. 
Consequentially, PD may be associated with lower risk of congestive heart failure 
(CHF) compared with HD3. These theoretical assumptions may influence modality 
selection in favor of PD, in incident dialysis patients with ESRD and ICMP, and 
warrant detailed examination. Accordingly, we aim to evaluate 2-year patient-
centered outcomes in this cohort with respect to initial dialysis modality. We 
hypothesize that patients on PD (versus HD) will experience less major adverse 
cardiac events (MACE), hospitalization days, and mortality over 2 years from dialysis 
initiation. 
 
We conducted a retrospective cohort sub-study, using a single-center, prospectively 
maintained database of 983 incident dialysis patients with ESRD, from 2005–2010. 
All demographics, comorbidities, and biochemistry were indexed at time of dialysis 
initiation. Routine 2D-echocardiogram was performed within 1 year of projected 
dialysis or 3 months of initiation. ICMP was defined as impaired resting left 
ventricular ejection fraction (LVEF) <45%, with documented coronary artery disease 
from coronary angiograms, stress tests, or prior acute myocardial infarction (AMI). 
Using this criterion, we identified 139 patients with ICMP. We examined the 
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differences in 2-year mortality, MACE, and hospitalization-days, in ICMP patients 
established on HD versus PD by 90 days from initiation. MACE includes AMI, 
coronary revascularization, CHF, and cerebrovascular event. Outcomes were 
expressed as incidence per 1000-dialysis days, and examined using Poisson 
regression. Hazard ratio for death was adjusted in the Cox-proportional hazard model, 
using a composite comorbid UREA5 score that stratifies local first-year mortality risk 
in ESRD, incorporating baseline mortality predictors including URate, LVEF, Age, 
Albumin, Alkaline phosphatase, and Arteriopathies (cerebrovascular disease and 
peripheral vascular disease)4. The cohort of interest includes 85 HD and 54 PD 
patients. Their profile and 2-year outcomes are detailed in TABLE 1. 86% had 
diabetic nephropathy, with median LVEF of 33%. Demographics and UREA5 
mortality-risk scores were comparable between HD and PD arms, except for more HD 
patients initiated on dialysis via temporary vascular access, and subtle differences in 
serum urate. Cumulative frequency and duration of hospitalization, and incidence of 
MACE over 2 years, were similar with either modality (TABLE 1). Modality 
conversions at 1 year were few. More HD patients were admitted for dialysis access 
malfunction (stenosis, thrombosis, bleeding), while more PD patients were admitted 
for access-related infection. This difference was not attributed to temporary HD 
catheter-related infections, which were 0.7 versus 0.4 per 1000-dialysis days in HD 
and PD groups, respectively (p=0.2). Overall 2-year mortality was near 50%. On 
multivariate analysis, hazard ratios for 1-year and 2-year mortality for HD versus PD 
were not statistically significant, before and after adjustment for UREA5 score 
(TABLE 2). 
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Our results demonstrate that patients with ESRD and ICMP initiated on PD versus 
HD did not experience improved 2-year mortality, cardiac and hospitalization 
outcomes, hence refuting our hypothesis. These findings are consistent with those 
reported from various registries, involving new ESRD patients with concomitant 
CHF, which did not report superior outcomes with PD versus HD5-7. 
 
This may be due to several reasons. Peritoneal glucose absorption and loss of protein 
in the dialysate may predispose patients to an atherogenic serum lipid profile8. 
Glucose absorption from the PD solution leads to poorer glycemic control in 
diabetics. Diabetes and ESRD synergistically increase the risk of cardiovascular 
events9. Therefore, theoretical benefits of PD and daily ultrafiltration may not 
translate to improved clinical outcomes. Nevertheless, HD may not be superior as it 
predisposes patients to intravascular volume contraction leading to cardiovascular 
instability, or contributing to earlier loss of residual renal function10. Our high 
prevalence of diabetes mellitus may impact negatively on vascular access maturity. 
 
Though our study is single-center with small sample size and subjected to selection 
bias with modality selection, the baseline profile appears well-matched between HD 
and PD arms in a very specific and unique cohort with advanced comorbidities. 
Furthermore, we could elaborate upon the disease burden by quantifying the LVEF 
and degree of vessel involvement on coronary angiography. Additionally, we adjusted 
the mortality risk with known predictors in our local ESRD cohort4.  
 
In the absence of randomized evidence guiding appropriate modality selection, our 
findings highlight that extended patient outcomes with PD versus HD in these ESRD 
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patients with significant cardiac disease are largely comparable. More attention 
should perhaps be paid to vascular access suitability for HD, and socio-economic 
factors affecting access infection risk for PD. These should highly influence 
clinicians, counselors, and patients in their joint decision for dialysis modality of 
choice at baseline. 
 
Disclosure Statement: 
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TABLE 1: Patient profile (HD versus PD as modality by 90 days from dialysis initiation) 
Variables Entire Cohort HD PD p-value 
    n = 139 n = 85 n = 54   
Age, mean (SD), yr 62 (10) 62 (9) 64 (11) 0.3 
Male gender, No. (%) 85 (61) 56 (66) 29 (54) 0.2 
Cause of ESRD, No. (%)               
  DM nephropathy 119 (86) 72 (85) 47 (87) 0.7 
  GN (presumed & Bx) 10 (7) 7 (8) 3 (6) 0.7 
  Hypertension 5 (4) 3 (4) 2 (4) 1.0 
  Others 5 (4) 3 (4) 2 (4) 1.0 
No permanent access at initiation, No. (%) 101 (73) 75 (88) 26 (48) <0.001 
CVA, No. (%) 26 (19) 15 (18) 11 (20) 0.7 
PVD, No. (%) 30 (22) 20 (24) 10 (19) 0.5 
Extent of ischemic heart disease               
  Prior AMI, No. (%) 95 (68) 63 (74) 32 (59) 0.07 
  LVEF, median (IQR), % 33 (27-38) 35 (28-38) 32 (25-38) 0.4 
  SVD on COROS, No. (%) 4 (3) 4 (5) 0 (0) 0.2 
  DVD on COROS, No. (%) 13 (9) 9 (11) 4 (7) 0.8 
  TVD on COROS, No. (%) 44 (32) 31 (36) 13 (24) 0.1 
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  Positive cardiac stress test(s), No. (%) 65 (47) 36 (42) 29 (54) 0.2 
  RWMA on resting 2DE, No. (%) 112 (81) 70 (82) 42 (78) 0.5 
Serum biochemistry at initiation               
  Hb, mean (SD), g/dL 9.4 (1.6) 9.4 (1.6) 9.6 (1.5) 0.5 
  Albumin, median (IQR), g/L 33 (28-36) 32 (29-36) 34 (28-37) 0.6 
  eGFR, median (IQR), ml/min/1.73m2 8 (6-10) 7 (6-10) 9 (6-11) 0.2 
  iPTH, median (IQR), pmol/L 22 (14-38) 25 (14-38) 22 (14-38) 0.6 
  ALP, median (IQR), U/L 87 (72-121) 86 (72-112) 87 (67-130) 0.9 
  Urate, mean (SD), µmol/L 553 (189) 527 (194) 594 (174) 0.04 
Modality switch at 1 yr*, No. (%) 8 (6) 3 (4) 5 (9) 0.3 
Hospitalization over 2 years (Poisson)**         
  Total RRT days over 2 years 67690 42685 25005   
  No. of admissions per 1000-days 12 (11-13) 12 (11-13) 13 (12-14) 0.1 
  Cumulative LOS per 1000-days 102 (99-104) 100 (97-103) 105 (101-109) 0.2 
  MACE, No. per 1000-days 4 (3-4) 3 (3-4) 4 (3-5) 0.4 
  Pneumonia, No. per 1000-days 1 (0-1) 1 (0-1) 1 (0-1) 0.4 
  Access infection, No. per 1000-days 1 (1-1) 1 (1-1) 2 (1-2) 0.005 
  Access malfunction, No. per 1000-days 2 (1-2) 2 (2-2) 1 (1-1) 0.001 
UREA5Ψ risk score, median (IQR) 4 (3-5) 4 (3-5) 4 (3-5) 0.1 
Mortality at 1 year, No. (%) 51 (37) 29 (34) 22 (41) 0.4 
Mortality at 2 years, No. (%) 68 (49) 38 (45) 30 (56) 0.2 
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*: Switch of modality from HD to PD and vice versa after 1 year from RRT initiation. 
**: Hospitalization data presented as incidence per 1000-RRT days over 2 years from RRT initiation (censored for mortality), and significance assessed 
using Poisson regression. 
Ψ: UREA5 1st year mortality risk score: calculated from known baseline predictors of early mortality locally, including URate, EF, Age, Albumin, ALP, 
Arteriopathy (CVA), Arteriopathy (PVD). 
2DE: 2D-echocardiogram;  ALP: alkaline phosphatase;  AMI: acute myocardial infarction;  Bx: kidney biopsy;  COROS: coronary angiogram;  CVA: 
cerebrovascular accident/disease;  d: day;  DM: diabetes mellitus;  DVD: double vessel disease;  EF: ejection fraction (see LVEF);  eGFR: estimated 
glomerular filtration rate;  ESRD: end-stage renal disease;  GN: glomerulonephritis;  Hb: hemoglobin;  HD: hemodialysis;  iPTH: intact parathyroid 
hormone;  IQR: interquartile range;  LOS: length of stay;  LVEF: left ventricular ejection fraction on echocardiography;  MACE: major adverse cardiac 
events;  No.: number;  PD: peritoneal dialysis;  PVD: peripheral vascular disease;  RRT: renal replacement therapy;  RWMA: regional wall motion 
abnormalities;  SD: standard deviation;  SVD: single vessel disease;  TVD: triple vessel disease;  yr: years. 
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TABLE 2: Cox proportional hazard regression for mortality 
    Hazard ratio 95% CI p-value 
Unadjusted 1st yr mortality       
     HD vs. PD by 90 days from RRT initiation 0.85 (0.49 - 1.48) 0.6 
     UREA5 score (per 1 pt increment from 0 to 5) 1.73 (1.27 - 2.35) <0.001 
Unadjusted mortality over 2 years from initiation       
     HD vs. PD by 90 days from RRT initiation 0.78 (0.48 - 1.26) 0.3 
     UREA5 score (per 1 pt increment from 0 to 5) 1.65 (1.28 - 2.13) <0.001 
Mortality prediction adjusted for UREA5 score       
     HD vs. PD on 1st yr mortality 0.96 (0.55 - 1.70) 0.9 
     HD vs. PD on 2 yr mortality 0.90 (0.55 - 1.47) 0.7 
CI: confidence interval;  HD: hemodialysis;  PD: peritoneal dialysis;  RRT: renal replacement therapy;  yr: year. 
  
